Immupharma PLC Board Appointment (4355F)

TIDMIMM

RNS Number : 4355F

Immupharma PLC

16 July 2021

ImmuPharma PLC

("ImmuPharma" or the "Company")

BOARD APPOINTMENT

ImmuPharma PLC (LSE:IMM) | Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, is delighted to announce the appointment of Dr Tim Franklin, Chief Operating Officer, to the Board of Directors.

Tim has worked with ImmuPharma for over three years, initially as a consultant and more recently was appointed as Chief Operating Officer in November 2020. Tim's key responsibilities include working closely with ImmuPharma's clinical team and scientific advisors, as the Company looks to further progress its wider drug development portfolio, both through clinical development and partnering opportunities.

In addition, Tim will lead the relationship with Avion Pharmaceuticals, as the Company advances Lupuzor(TM) through its Phase 3 trial and regulatory processes involved in the ultimate approval of the drug.

Tim has over 30 years' experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Commenting on the appointment, Tim McCarthy, Chairman said: "It is a pleasure to welcome Tim onto the Board of Directors. Tim has made an invaluable contribution to ImmuPharma over the last three years. During this time, he played a key role in negotiations, which resulted in the successful conclusion of the licensing deal with Avion Pharmaceuticals, our partner for Lupuzor(TM), which is now close to embarking on its international Phase 3 trial. His extensive pharmaceutical and capital markets experience will contribute enormously to the team as we look to move into the next phase of our journey for the Company."

End

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Timothy Gary Franklin (aged 57).

 
 Current Directorships   Past Directorships held within 
                          last 5 years 
 None                    Zalzana Limited 
                          SynDermix AG

Dr Tim Franklin currently holds 1.5 million options over ordinary shares in the Company.

Save as disclosed above there are no additional disclosures to be made in accordance with Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies in respect of the appointment of Dr Tim Franklin.

 
 For further information please contact: 
   ImmuPharma PLC ( www.immupharma.com ) 
    Tim McCarthy, Chairman                        + 44 (0) 207 152 4080 
   Dimitri Dimitriou, Chief Executive Officer 
   Lisa Baderoon, Head of Investor Relations      + 44 (0) 7721 413496 
   SPARK Advisory Partners Limited (NOMAD) 
    Neil Baldwin 
 
    Stanford Capital Partners (Joint Broker)      +44 (0) 203 36 8 3550 
    Patrick Claridge 
    John Howes 
    Bob Pountney                                   +44 (0) 203 815 8880 
 
    SI Capital (Joint Broker) 
    Nick Emerson                                   +44 (0) 1483 413500 
   4Reliance (Euronext Growth Listing Sponsor)    +32 (0) 2 747 02 60 
    Jean-Charles Snoy 
 
    Degroof Petercam (Liquidity Provider)          +32 (0) 2 287 95 34 
    Erik De Clippel 
 
    Backstage Communication 
    Olivier Duquaine                               +32 (0) 477 504 784 
    Gunther De Backer                              +32 (0) 475 903 909

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor(TM), is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor(TM) to fund a new international Phase 3 trial for Lupuzor(TM) and commercialise in the US.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOADKPBPCBKDNOD

(END) Dow Jones Newswires

July 16, 2021 02:00 ET (06:00 GMT)

Immupharma (LSE:IMM)
Historical Stock Chart
From Sep 2024 to Oct 2024